Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 4
1(25.0%)
N/A
1(25.0%)
4Total
Phase 1(2)
Phase 4(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00139139Not ApplicableCompleted

A Study to Compare the Efficacy of Hepatitis A Vaccine and Immune Globulin When Given After Exposure to Hepatitis A

Role: collaborator

NCT02501421Phase 1Completed

Reactogenicity, Safety and Immunogenicity of a TB/FLU-04L Tuberculosis Vaccine

Role: collaborator

NCT03017378Phase 1Completed

Reactogenicity, Safety and Immunogenicity of a TB/FLU-01L Tuberculosis Vaccine

Role: collaborator

NCT01700075Phase 4Completed

Physical and Chemical Study of Atherosclerosis Mechanisms

Role: collaborator

All 4 trials loaded